For the year ending 2025-12-31, NRXP has $12,956K in assets. $28,893K in debts. $7,797K in cash and cash equivalents.
| Balance Sheets | 2025-12-31 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 7,797 | |||
| Accounts receivable, net | 161 | |||
| Prepaid expense and other current assets | 934 | |||
| Total current assets | 8,892 | |||
| Investments | 397 | |||
| Ppe | 93 | |||
| Nrx Segment | 23 | |||
| Dura Segment | 7 | |||
| Less accumulated depreciation | 30 | |||
| Furniture and equipment, net | 63 | |||
| Right-of-use assets, net-Nonrelated Party | 414 | |||
| Right-of-use assets, net-Related Party | 219 | |||
| Intangible assets, net (provisional) | 925 | |||
| Goodwill (provisional) | 1,793 | |||
| Other assets | 253 | |||
| Total assets | 12,956 | |||
| Accounts payable | 4,270 | |||
| Accrued and other current liabilities | 11,337 | |||
| Accrued clinical site costs | 351 | |||
| Convertible note payable and accrued interest, current | 0 | |||
| Insurance loan payable | 0 | |||
| Warrant liabilities | 12,304 | |||
| Lease liability, short term-Nonrelated Party | 211 | |||
| Lease liability, short term-Related Party | 105 | |||
| Total current liabilities | 28,578 | |||
| Convertible note payable and accrued interest, long term | 0 | |||
| Lease liability, noncurrent-Nonrelated Party | 199 | |||
| Lease liability, noncurrent-Related Party | 116 | |||
| Total liabilities | 28,893 | |||
| Preferred stock-Nondesignated Preferred Stock | 0 | |||
| Preferred stock-Series AConvertible Preferred Stock | 0 | |||
| Common stock, 0.001 par value, 500,000,000 shares authorized 31,734,333 and 14,591,505 shares issued and outstanding as of december 31, 2025 and 2024, respectively | 32 | |||
| Additional paid-in capital | 290,926 | |||
| Accumulated deficit | -306,895 | |||
| Total stockholders deficit | -15,937 | |||
| Total liabilities and stockholders' deficit | 12,956 | |||
NRX Pharmaceuticals, Inc. (NRXP)
NRX Pharmaceuticals, Inc. (NRXP)